Table 1.
Baseline characteristics of enrolled participants
| Variablea | Inactivated vaccine (n = 100)b | Ad5-nCoV (n = 100) |
|---|---|---|
| Sex | ||
| Male | 55 (55.0) | 55 (55.0) |
| Female | 45 (45.0) | 45 (45.0) |
| Age | ||
| 18–59 years | 59 (59.0) | 60 (60.0) |
| 60–80 years | 41 (41.0) | 40 (40.0) |
| Median age (IQR), years | 49 (38.0, 64.0) | 45.7 (37.3, 63.0) |
| Body mass index (kg/m2) | ||
| ≤18.4 | 1 (1.0) | 4 (4.0) |
| 18.5–24.9 | 65 (65.0) | 48 (48.0) |
| 25.0–29.9 | 30 (30.0) | 40 (40.0) |
| ≥30.0 | 4 (4.0) | 8 (8.0) |
| Time interval since the last priming dose of inactivated vaccine, months | ||
| Median (IQR) | 6.7 (6.3, 6.9) | 6.7 (6.3, 6.9) |
| Underlying chronic diseasesc | ||
| Yes | 27 (27.0) | 32 (32.0) |
| No | 73 (73.0) | 68 (68.0) |
aData are the number of participants (%) or median (IQR).
b62 participants received CoronaVac, and 38 participants received Covilo. Underlying chronic diseases included cardiovascular and cerebrovascular diseases, hypertension, and chronic obstructive pulmonary disease.